Moderna and Pfizer-BioNTech say they’re beginning trials to assess the safety, efficacy and dosage of their candidate vaccine that combines four flu strains and two coronavirus strains. Health experts say these combination vaccines could be available as early as next flu season.
Ideally, these vaccines would protect against COVID-19 and the flu with a single shot.
Vaccine developers are using their candidate flu vaccines that use mRNA technology and combining it with their bivalent booster. The combination vaccines induce an immune response specific to the four strains of flu circulating that season, the original coronavirus, and the BA.4/BA.5 subvariants.
Read the full article here.